OMEX compared with ABUS: revenue, margins and what each company keeps, and the suppliers and customers both name

OMEXOdyssey Marine Exploration Inc

Mkt capRevenueRevenue

ABUSArbutus Biopharma Corp

Mkt capRevenueRevenue

Compare

OMEXOdyssey Marine Exploration Inc

ABUSArbutus Biopharma Corp

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

OMEX

No earnings history for OMEX.

ABUS

0 of 3at or beyond implied

Reportimpliedrealized× implied

Q2 FY26—▼−1.71%—

May 13 '26±6.5%0.00%×0.00

Q1 FY26±13.7%▲+4.25%×0.31

Q3 FY25±22.5%▼−5.79%×0.26

= impliedOMEX realized, solidABUS realized, hatchedOne scale, both sides: full bar = 23%× = |realized| ÷ impliedSource: market data

OMEXOdyssey Marine Exploration Inc

13.50▲+2.74%· post 10.70

Mkt cap$26.5MRevenue$77,855Q2 FY26Revenue$353,719FY25

ABUSArbutus Biopharma Corp

4.20▼−1.82%· post 4.20

ClosedOct 30 '26

Mkt cap$832.9MRevenue$1MQ2 FY26Revenue$14MFY25

Compare

ClosedOct 30 '26

OMEXOdyssey Marine Exploration Inc

ABUSArbutus Biopharma Corp

13.50▲+2.74%post 10.70

Price

4.20▼−1.82%post 4.20

$26.5M

Mkt cap

$832.9M

Q2 FY26$77,855

Revenue

$1MQ2 FY26

FY25$353,719

Revenue

$14MFY25

OMEX13.50▲+2.74%vsABUS4.20▼−1.82%ClosedOct 30 '26